UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB

Thomas, AJ; Attems, J; Colloby, SJ; O'Brien, JT; McKeith, I; Walker, R; Lee, L; ... Walker, Z; + view all (2017) Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB. Neurology , 88 (3) pp. 276-283. 10.1212/WNL.0000000000003512. Green open access

[thumbnail of Thomas_Autopsy_validation_123I-FP-CIT.pdf]
Preview
Text
Thomas_Autopsy_validation_123I-FP-CIT.pdf - Published Version

Download (596kB) | Preview

Abstract

OBJECTIVE: To conduct a validation study of (123)I-N-fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl) nortropane ((123)I-FP-CIT) SPECT dopaminergic imaging in the clinical diagnosis of dementia with Lewy bodies (DLB) with autopsy as the gold standard. METHODS: Patients >60 years of age with dementia who had undergone (123)I-FP-CIT imaging in research studies and who had donated their brain tissue to the Newcastle Brain Tissue Resource were included. All had structured clinical research assessments, and clinical diagnoses were applied by consensus panels using international diagnostic criteria. All underwent (123)I-FP-CIT imaging at baseline, and scans were rated as normal or abnormal by blinded raters. Patients were reviewed in prospective studies and after death underwent detailed autopsy assessment, and neuropathologic diagnoses were applied with the use of standard international criteria. RESULTS: Fifty-five patients (33 with DLB and 22 with Alzheimer disease) were included. Against autopsy diagnosis, (123)I-FP-CIT had a balanced diagnostic accuracy of 86% (sensitivity 80%, specificity 92%) compared with clinical diagnosis, which had an accuracy of 79% (sensitivity 87%, specificity 72%). Among patients with DLB, 10% (3 patients) met pathologic criteria for Lewy body disease but had normal (123)I-FP-CIT imaging. CONCLUSIONS: This large autopsy analysis of (123)I-FP-CIT imaging in dementia demonstrates that it is a valid and accurate biomarker for DLB, and the high specificity compared with clinical diagnosis (20% higher) is clinically important. The results need to be replicated with patients recruited from a wider range of settings, including movement disorder clinics and general practice. While an abnormal (123)I-FP-CIT scan strongly supports Lewy body disease, a normal scan does not exclude DLB with minimal brainstem involvement. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that (123)I-FP-CIT dopaminergic neuroimaging accurately identifies patients with DLB.

Type: Article
Title: Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1212/WNL.0000000000003512
Publisher version: http://dx.doi.org/10.1212/WNL.0000000000003512
Language: English
Additional information: Copyright © 2016 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Division of Psychiatry
URI: https://discovery-pp.ucl.ac.uk/id/eprint/1532763
Downloads since deposit
3,600Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item